Technology | Vascular Closure Devices | April 10, 2018

Vascade Vascular Closure System Approved for Femoral Vein Closure

Cardiva Medical’s device now indicated for both arterial and venous vascular closure

Vascade Vascular Closure System Approved for Femoral Vein Closure

April 10, 2018 – Cardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.

The Vascade System consists of a thrombogenic bioabsorbable collagen patch and proprietary collapsible disc technology that is clinically proven to safely and effectively achieve hemostasis while minimizing complications, according to the company. Unlike manual compression, which is the current standard for femoral access site closure, Vascade does not require prolonged, heavy pressure and extended bed rest to ensure hemostasis.

“Vascade has performed exceptionally well for our current patients, and this new indication will empower many physicians to use Vascade for vein closure," said Joseph De Gregorio, M.D., chief of invasive cardiology at Englewood Hospital and Medical Center in New Jersey. "Successful vessel closure, and enabling a patient to walk as soon as possible after their procedure, are critical factors for recovery from interventional procedures. The ease of use of the Vascade system and its compelling clinical data will make it an attractive new option for closure following vein procedures.”  

Results of a study evaluating Vascade for venous closures were published in Vascular Disease Management. The authors noted that the “device achieved complete hemostasis without any recorded vascular complications, and was effective in providing earlier ambulation and discharge compared with our standard protocol for manual compression.” In the same article, the authors emphasize that access site complications remain the most common complication from cardiac catheterization procedures that require venous access.[1]

Vascade is commercially available in the United States, where it has been approved by the FDA (2013), and has received CE mark (2012).

For more information: www.cardivamedical.com

 

Reference:

1. Nagabandi, A. et al. Use of Vascade Vascular Closure System for Venous Hemostasis.  Vascular Disease Management; 2017;14(8):E171-E173.

Related Content

360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Videos | Cath Lab | March 27, 2018
Roxana Mehran, M.D., FACC, FACP, FCCP, FESC, FAHA, FSCAI, professor of medicine and director of interventional cardio
American College of Cardiology Expands Patient Navigator Program
News | Cath Lab | March 21, 2018
March 21, 2018 — Hundreds of hospitals across the United States will have access to tools and resources to help impro
Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
Overlay Init